Answers are grounded in this paper and cite their sources.
Aims Short‐term insulin‐based therapy can induce remission of Type 2 diabetes (T2DM) in some but not all patients. The underlying determinant of whether remission can be achieved is beta‐cell function, but its assessment typically requires complex challenge testing. We thus sought to determine if there exist circulating biomarkers associated with the likelihood of achieving remission prior to initiating short‐term insulin‐based therapy, without requiring challenge testing. Methods Adults with T2DM of ≤ 7 years duration were randomized to 8 weeks treatment with (i) insulin glargine, (ii) glargine + thrice‐daily lispro or (iii) glargine + twice‐daily exenatide, followed by 12 weeks washout that enabled assessment for remission (A1c < 6.5% after ≥ 3 months without glucose‐lowering therapy). We assessed the following fasting biomarkers at baseline in relation to subsequent remission: fibroblast growth factor‐21 (FGF‐21), C‐reactive protein (CRP), vascular cell adhesion molecule‐1 (VCAM‐1), interleukin‐1β (IL‐1β), interleukin‐6 (IL‐6), interleukin‐4 (IL‐4), monocyte chemoattractant protein‐1 (MCP‐1) and dipeptidyl peptidase‐4 (DPP‐4). Results Remission occurred in 31 of 90 participants (34.4%). At baseline, compared to their non‐remitting peers, those in whom remission was subsequently achieved had higher Homeostasis Model Assessment of beta‐cell function (HOMA‐B; p = 0.02), lower fasting proinsulin: C‐peptide ratio ( p = 0.008) and borderline higher prevalence of detectable IL‐4 ( p = 0.06), though significance did not persist after multiplicity‐adjustment. On exploratory logistic regression analyses, baseline detectable IL‐4 (aOR = 3.58; 95% CI: 1.25–10.99) and HOMA‐B (aOR = 1.77; 95% CI: 1.11–2.99) were associated with remission. Conclusion Prior to treatment, higher HOMA‐B and detectable IL‐4 are candidate markers warranting further study for association with subsequent remission of T2DM in response to short‐term insulin‐based therapy.
No takes yet. Share an insight, caveat, or question.
THIYAGARAJAH et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: